Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2017-10-26 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2017年第三季度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (440 characters) indicating that the company's full 2017 third quarter report has been approved and is available on the official disclosure website. It does not contain the actual financial data or the full report itself, but rather informs investors about the availability of the report. According to the 'Menu vs Meal' rule, such a brief notice that points to the report's publication is classified as a Report Publication Announcement (RPA).
2017-10-26 Chinese
第二届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board (监事会) of 贝达药业股份有限公司 regarding the approval of the company's 2017 third quarter report. It states that the full 2017 third quarter report was reviewed and approved, and that the full report is available on the official disclosure website. The document itself is short (1051 characters) and does not contain the actual financial data or the full report, but rather announces the supervisory board's meeting and approval of the report. According to the 'Menu vs Meal' rule, this is an announcement related to a report, not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not contain substantive financial data themselves.
2017-10-26 Chinese
关于对外投资成立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the establishment of wholly-owned subsidiaries through external investments. It details the board meeting resolutions, investment amounts, company registration information, and the strategic purpose and risks of the investments. The document is relatively short (2975 characters) and focuses on corporate actions related to investment and subsidiary formation. It does not contain financial statements, audit information, or detailed financial performance data. It is not a report but an announcement of corporate investment activities. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as establishing subsidiaries through investment.
2017-10-26 Chinese
2017年第三次临时股东大会的法律意见书
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of a specific shareholders' meeting (the 2017 third extraordinary general meeting) of Betta Pharmaceuticals Co., Ltd. It details the legal compliance of the meeting's call, attendance, agenda, and voting process, and confirms the legality and validity of the voting results. The document does not contain financial statements or management discussion of financial results, nor is it a report of voting results alone. It is a legal opinion related to a shareholders' meeting, which is typically classified under Board/Management Information (MANG) as it relates to governance and management matters. It is not an announcement of voting results (DVA) because it includes legal opinion on the meeting's procedures and validity, not just the voting outcome. Therefore, the best fitting category is MANG with high confidence.
2017-10-12 Chinese
2017年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2017 third extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1826 characters) and it is not a report publication announcement but the actual voting results announcement. Therefore, the correct classification is DVA with high confidence.
2017-10-12 Chinese
2017年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2017, providing estimated net profit figures and explanations for the expected decline. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the upcoming third quarter report. The document is short (1082 characters) and serves as an announcement of expected financial results rather than a full interim or quarterly report containing actual financial statements. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. 9M 2017
2017-10-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.